← Leaderboards
Dhaval K Shah
State University Of New York At Buffalo
$3,768,811
Attributed
$5,887,174
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,887,174 · 4
By mechanism
R01$5,887,174 · 4
Top collaborators
- Joseph P Balthasar8 shared
- Ravikumar N Majeti4 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Joseph P Balthasar$10,000,685
- Sriram Neelamegham$14,753,332
Others in their field
Top investigators on “Mathematical Model”
- Deborah J Donnell · Fred Hutchinson Cancer Center$140,607,304
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,263,426
- Myron S Cohen · Family Health International$91,263,426
- Gregory D Peterson · University Of Tennessee Knoxville$84,527,696
- Robert A Kamphaus · University Of Washington$83,310,874
- Anders Ryd · Cornell University$79,389,944
Research focus
Mathematical ModelIn VivoAffinityDesignPharmaceutical PreparationsIn VitroTranslationsSiteDrug KineticsTumorMonoclonal AntibodiesAntibody-Drug ConjugatesMouse ModelResearch Clinical TestingCharacteristicsPre-ClinicalDoseOncologyTumor AntigensIn SilicoAntibodiesInvestigationNovel StrategiesBinding Sites
Grant awards (18)
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia$427,572
R01 · FY2025 · CA
Polyesters with controlled topologies for probing transcytosis at the gut-blood barrier$367,937
R01 · FY2025 · GM
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia$406,193
R01 · FY2024 · CA
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors$344,980
R01 · FY2024 · CA
Polyesters with controlled topologies for probing transcytosis at the gut-blood barrier$326,110
R01 · FY2024 · GM
Proposal for Administrative supplement to Purchase NanoSight Pro$171,763
R01 · FY2024 · GM
Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia$426,903
R01 · FY2023 · CA
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors$355,916
R01 · FY2023 · CA
Polyesters with controlled topologies for probing transcytosis at the gut-blood barrier$328,441
R01 · FY2023 · GM
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors$355,425
R01 · FY2022 · CA
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors$362,722
R01 · FY2021 · CA
Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors$362,764
R01 · FY2020 · CA
Translational Systems Pharmacokinetic Models of Novel Anticancer Biologics$288,342
R01 · FY2019 · GM · contact PI
Translational Systems Pharmacokinetic Models of Novel Anticancer Biologics$289,679
R01 · FY2018 · GM · contact PI
Translational Systems Pharmacokinetic Models of Novel Anticancer Biologics$189,161
R01 · FY2018 · GM · contact PI
Translational Systems Pharmacokinetic Models of Novel Anticancer Biologics$290,895
R01 · FY2017 · GM · contact PI
Translational Systems Pharmacokinetic Models of Novel Anticancer Biologics$292,002
R01 · FY2016 · GM · contact PI
Translational Systems Pharmacokinetic Models of Novel Anticancer Biologics$300,369
R01 · FY2015 · GM · contact PI